Actavis Confirms Generic Fortesta Patent Challenge

Actavis, Inc. (NYSE: ACT ) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone gel 10mg/0.5g. Actavis' ANDA product is a generic version of Endo Pharmaceuticals' Fortesta^®, which is indicated for replacement therapy in males for conditions associated